<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745719</url>
  </required_header>
  <id_info>
    <org_study_id>A111-102</org_study_id>
    <nct_id>NCT00745719</nct_id>
  </id_info>
  <brief_title>Parathyroidectomy in Endstage Renal Disease</brief_title>
  <official_title>A Pilot Study to Evaluate the Efficacy of Total Parathyroidectomy in Retarding Cardiovascular Calcification in End-stage Renal Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypothesis that total parathyroidectomy retards cardiovascular calcification,&#xD;
      improves bone mineral density, reduces cardiac hypertrophy and arterial stiffening in&#xD;
      end-stage renal disease patients on maintenance dialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary hyperparathyroidism (SHPT) in patients with end-stage renal disease contributes to&#xD;
      increased cardiovascular morbidity and mortality via different mechanisms. Uncontrolled&#xD;
      hyperparathyroidism is associated with left ventricular hypertrophy and has been implicated&#xD;
      in the development of cardiac interstitial fibrosis and diastolic dysfunction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Parathyroidectomy group versus natural disease control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vascular and valvular calcium scores</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in aortic pulse wave velocity,</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in left ventricular mass, volume and function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in quality of life scores</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in iPTH</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in Serum calcium and phosphate</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in alkaline phosphatase</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in handgrip strength</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in subjective global assessment</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in serum albumin</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in inflammatory marker</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in HOMA index</measure>
    <time_frame>6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Endstage Renal Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>surgical total parathyroidectomy with forearm autografting</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>parathyroidectomy</intervention_name>
    <description>total parathyroidectomy with forearm autografting</description>
    <arm_group_label>1</arm_group_label>
    <other_name>total parathyroidectomy with forearm autografting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Endstage renal disease patients receiving either long-term hemodialysis or peritoneal&#xD;
             dialysis treatment, with elevated intact parathyroid hormone (iPTH) levels &gt; 500pg/ml&#xD;
             on two or more occasions.&#xD;
&#xD;
          -  Patients with parathyroid nodular or diffuse hyperplasia identified by ultrasound&#xD;
             imaging or radioisotope scan.&#xD;
&#xD;
          -  Patients who provide informed consent for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with significant background valvular heart disease&#xD;
&#xD;
          -  Patients who are unfit for general anaesthesia&#xD;
&#xD;
          -  Patients with acute myocardial infarction within recent two months&#xD;
&#xD;
          -  Patients with poor general condition&#xD;
&#xD;
          -  Patients with plans for living related kidney transplant within 1 year&#xD;
&#xD;
          -  Patients with previous history of parathyroidectomy&#xD;
&#xD;
          -  Patients with calciphylaxis&#xD;
&#xD;
          -  Patients with underlying active malignancy&#xD;
&#xD;
          -  Patients with contraindication for MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela YM Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital, Tung Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>0000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 1, 2008</study_first_submitted>
  <study_first_submitted_qc>September 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>August 2, 2020</last_update_submitted>
  <last_update_submitted_qc>August 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Angela Yee-Moon Wang</investigator_full_name>
    <investigator_title>Honorary Associate Professor</investigator_title>
  </responsible_party>
  <keyword>parathyroidectomy</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>bone</keyword>
  <keyword>endstage renal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

